Open-Label Placebo for Chronic Pain: What Studies Show

“It might be a placebo effect” can sound like someone is dismissing your relief. The research asks a more interesting question: which parts of a treatment experience helped, how much did they help, and how long did the change last?

Sarah Pressman’s lecture turns to placebo effects around 26 minutes. Later research helps separate promising findings from claims that go beyond the evidence.

Improvement in a placebo group is not all a placebo effect

If a person improves after receiving a placebo, several explanations remain possible. Symptoms fluctuate. People often seek treatment during a particularly bad period, which may ease naturally. Other care may continue. The attention, explanation, and expectations surrounding treatment may also contribute.

A Cochrane review of placebo interventions emphasized the need for comparisons with no-treatment groups when estimating placebo effects. Simply measuring improvement in a placebo arm does not isolate what the placebo caused.

That distinction is useful whenever a treatment is advertised with a before-and-after story. Ask what the comparison group received, whether participants knew their assignment, and whether the outcome was pain, function, or something else.

What the knee-surgery example actually tested

The lecture includes a well-known 2002 trial by J. Bruce Moseley and colleagues. It randomized 180 people with knee osteoarthritis to arthroscopic lavage, debridement, or a simulated procedure. Over two years, the active procedures did not provide better pain or function outcomes than the placebo procedure.

The placebo group received skin incisions and simulated surgery without insertion of the arthroscope. This corrects a procedural detail in the lecture. More broadly, the result concerned those procedures for knee osteoarthritis. It did not test knee replacement or every operation used for knee pain.

The authors also noted that improvement in the placebo group could reflect natural history or a placebo effect. The trial is a strong reason to ask whether a proposed procedure has specific benefit. It is not proof that belief repairs a joint.

Can a placebo work without deception?

That is the question open-label studies try to answer. Participants are told what they are receiving. The explanation and treatment setting are part of the intervention, so the research is about more than the contents of a pill or syringe.

A 2025 systematic review of four chronic low back pain studies, involving 332 participants, found a modest average pain difference favoring open-label placebo: about 0.62 points on a 0-to-10 scale. The authors rated the certainty of that finding as very low because of study limitations and potential bias.

That average cannot predict whether an individual will benefit. It also should not be presented as a reliably established treatment effect. Unblinded interventions and patient-reported outcomes make careful study design especially important.

Short-term relief and lasting benefit are different questions

In a 2024 randomized trial of 101 adults with chronic back pain, participants received either usual care or a single saline injection openly described as a placebo, with an accompanying explanation, alongside ongoing care.

The placebo group had lower pain intensity at one month, with a between-group difference of about 0.61 points on a 0-to-10 scale. The pain benefit did not persist through the one-year follow-up. Some secondary outcomes, including mood and sleep disruption, showed longer-lasting benefits.

This was a particular clinician-delivered procedure in a research setting. It does not establish that buying placebo pills, using an AI companion, or expecting a treatment to work will produce the same result. It is not a recommendation to seek a placebo injection.

Honesty belongs in the treatment conversation

You should be able to ask for a clear explanation of the treatment, the expected benefit, the uncertainty, the cost, and the alternatives. If someone suggests an open-label placebo, ask whether it is part of research or clinical care, what usual treatment will continue, and how progress will be assessed.

There is room for hope without a guarantee. A useful explanation might say that an approach helps some people, identify the evidence, and agree on a review point. Insisting that it will work if you believe strongly enough puts responsibility for an uncertain result on the patient.

Persistent pain after a treatment is information for the care plan. It does not demonstrate a failure to trust, imagine, or try. Our coordinated care guide describes why several forms of support may need to work together.

How Cindra should handle expectations

Cindra should explain the evidence behind a suggested exercise in ordinary language. It should distinguish something a user finds comforting from something shown to treat a condition. If an exercise feels helpful, that experience can be acknowledged without inventing a mechanism.

The platform should never secretly substitute a placebo for treatment, disguise uncertainty to increase confidence, or treat symptom improvement as proof that a disease was absent. It should make it easy to record no benefit or unwanted effects.

Those are proposed design requirements for Cindra. They would need testing in the platform itself, including whether users understand the uncertainty and feel able to disagree with its suggestions.

Educational commentary and proposed product requirements. Sources checked October 27, 2026. This article has not undergone clinical review and does not provide an individualized care plan. Cindra requires product-specific evaluation before clinical benefit can be claimed.